MedTrace Logo

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

NCT03134118 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-05-15

No results posted yet for this study

Summary

The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.

Conditions

  • Thymoma Type B3
  • Thymic Carcinoma

Interventions

DRUG

Nivolumab

Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks

Sponsors & Collaborators

  • ETOP IBCSG Partners Foundation

    collaborator NETWORK

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Nicolas Girard · Institut Curie, Paris, France

  • Solange Peters · University of Lausanne Hospitals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-11
Primary Completion
2023-09-05
Completion
2027-12-31

Countries

  • Belgium
  • France
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03134118 on ClinicalTrials.gov